Figure 4

3,4-Difluorobenzocurcumin inhibits pathological phenotypes associated with vegfc overexpression. (A?G?) Lateral confocal images of either a 3 dpf Tg(prox1a:KALTA4,4xUAS-E1B:TagRFP);Tg(fli1a:nEGFP) larva (Non-vegfc-induced) treated with 0.1% DMSO (A,A?), or 3 dpf Tg(prox1a:KALTA4,4xUAS-E1B:TagRFP);Tg(10XUAS:vegfc);Tg(fli1a:nEGFP) larvae (vegfc-induced) treated with either 0.1% DMSO (B,B?), 4 ?M SL327 (C,C?), 20 ?M sunitinib malate (SM, D,D?), 10 ?M curcumin (CM, E,E?), 2,5 ?M 3,4-Difluorobenzocurcumin (CDF, F,F?), or 5 ?M CDF (G,G?). Pathological vascular phenotypes in vegfc-induced embryos are rescued by CDF treatment. Images (A??G?) represent the Tg(prox1a:KALTA4,4xUAS-E1B:TagRFP) expression of images (A?G). To avoid the robust prox1a expression in muscle cells, (A??G?) are maximum projection images of only the z stacks that contain the posterior cardinal vein. Images (B?) (21/22 embryos), (E?) (23/23 embryos) and (F?) (14/20 embryos) show embryos with increased prox1a:KALTA4,4xUAS-E1B:TagRFP expression in venous endothelial cells. This pathological phenotype is rescued in images (C?) (20/20 embryos), (D?) (27/27 embryos) and (G?) (21/24 embryos). (H) Quantification of fli1a:EGFP-positive ECs across 4.5 somites in either 3 dpf non-vegfc-induced treated with 0.1% DMSO (n = 21 embryos) or 3 dpf vegfc-induced larvae treated with either 0.1% DMSO (n = 22 embryos), 4 ?M SL327 (n = 20 embryos), 20 ?M SM (n = 27 embryos), 10 ?M CM (n = 23 embryos), or CDF at 2.5 ?M (n = 20 embryos) or 5 ?M (n = 24 embryos). PCV: posterior cardinal vein. Statistical test: Kruskal-Wallis test was conducted for graph H. p ? 0.001 (***) and n.s. indicates not significant. Scale bar: 100 ?m.